Siemens has rebranded and will expand its Healthcare business. The imaging and laboratory diagnostics giant has, perhaps a bit awkwardly, rebranded the business as Siemens Healthineers. The group is a separately managed business within the larger corporate structure, a transition that happened early last year.
Dexcom is working to up its commercial game in Europe. The latest part of that plan is an acquisition of its distributor in Germany, Switzerland and Austria: Nintamed.
Royal Philips has big plans in HealthTech. But to execute on them, it needs to rid itself of its lighting businesses and, in the process, gain some liquidity to reinvest into health technology, which is expected to be the future of the transitioning industrial conglomerate that has traditionally spanned consumer, healthcare and lighting businesses.
Royal Philips may be starting to achieve the mid- to high-single-digit growth it previously articulated for its HealthTech portfolio. But Wall Street remained a bit skeptical as the disposal of its Lighting businesses continues to drag on, muddying the new story Philips is trying to focus on.
G-Therapeutics raised €36 million ($41 million) in a Series A round and debt to finish developing and start clinical trials for its Implantable Neuro-stimulation System to restore lower limb function, including walking, to patients suffering from paralysis due to spinal cord injury.
iStar Medical raised a €10 million ($11.4 million) Series B round to fund a study to support a CE mark for its latest product. Its MiniJect is an injected implant that is designed to reduce intraocular pressure in glaucoma patients by improving aqueous humor outflow from the anterior chamber to the suprachoroidal space.
Stat-Diagnostica expects to start marketing its DiagCore Near Patient Testing System in Europe next year. To help get it there, the Barcelona, Spain-based startup has raised a €25 million ($28.5 million) Series C round led by prominent European investor Gilde Healthcare.
IBM's Watson Health Unit announced it will open its first Watson Health European Center of Excellence in Milan, Italy.
Founded more than 20 years ago, glucose monitor implant startup Senseonicsy is now hoping that it can get regulators to sign off on its continuous glucose monitor Eversense that's based on a tiny implant to track diabetics for up to 90 days. That's much longer than the typical 5- to 7-day span that's available for popular patch-based CGMs.
Philips is slated to report with a reorganized business structure that better reflects its HealthTech priorities for the first time with its first-quarter earnings due at the end of April. Philips' CEO Frans van Houten said that he's looking for mid- to high-single-digit growth from each of the three new segments: Connected Care & Health Informatics; Diagnosis & Treatment; and Personal Health.